We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+6.83%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.32B
AUM Growth
-$100M
(-7%)
Cap. Flow
-$118M
Cap. Flow
% of AUM
-8.94%
Top 10 Holdings %
Top 10 Hldgs %
27.68%
Holding
135
New
38
Increased
26
Reduced
44
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
|
+$30.5M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$27.4M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$26.1M |
| 4 |
ACCD
Accolade Inc
ACCD
|
+$22.7M |
| 5 |
Vor Biopharma
VOR
|
+$22.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$40.6M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$35M |
| 3 |
Exelixis
EXEL
|
+$29.6M |
| 4 |
Labcorp
LH
|
+$28.8M |
| 5 |
AFIB
Acutus Medical Inc
AFIB
|
+$28.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.61% |
| 2 | Industrials | 3.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Exelixis
EXEL
$13.3B
| $11.1M | 0.84% |
490,058
-1,312,212
| -73% | -$29.6M |
|
52
Guardant Health
GH
$21.7B
| $10.9M | 0.83% |
71,386
-7,600
| -10% | -$1.15M |
|
|
EPIX
53
DELISTED
ESSA Pharma
EPIX
| $10.8M | 0.82% |
+371,963
| New | +$8.65M |
|
54
Bolt Biotherapeutics
BOLT
$7.67M
| $10.5M | 0.8% |
+16,001
| New | +$10.4M |
|
55
AbbVie
ABBV
$443B
| $9.9M | 0.75% |
91,500
-3,750
| -4% | -$401K |
|
56
Abbott
ABT
$183B
| $9.55M | 0.72% |
79,698
| – | – |
|
57
Instil Bio
TIL
$48.3M
| $9.46M | 0.72% |
+18,863
| New | +$9.68M |
|
58
Pulmonx
LUNG
$68.8M
| $9.28M | 0.7% |
+202,900
| New | +$11.6M |
|
59
Molina Healthcare
MOH
$10.2B
| $8.86M | 0.67% |
37,897
-75
| -0.2% | -$16.7K |
|
60
UnitedHealth
UNH
$376B
| $8.8M | 0.67% |
23,650
-1,812
| -7% | -$628K |
|
61
Eli Lilly
LLY
$1.02T
| $8.73M | 0.66% |
46,715
-4,850
| -9% | -$949K |
|
|
CTLT
62
DELISTED
CATALENT, INC.
CTLT
| $8.24M | 0.62% |
+78,250
| New | +$8.73M |
|
|
FRLN
63
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $8.05M | 0.61% |
43,633
-200
| -0.5% | -$47.4K |
|
64
Bristol-Myers Squibb
BMY
$133B
| $7.93M | 0.6% |
125,574
-20,000
| -14% | -$1.24M |
|
|
MTEM
65
DELISTED
Molecular Templates, Inc.
MTEM
| $7.78M | 0.59% |
41,097
+26,130
| +175% | +$4.58M |
|
|
SGEN
66
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.28M | 0.55% |
52,406
-5,700
| -10% | -$918K |
|
|
EXAS
67
DELISTED
Exact Sciences
EXAS
| $7.25M | 0.55% |
+55,000
| New | +$7.53M |
|
|
LITS
68
Lite Strategy Inc
LITS
$32.8M
| $6.73M | 0.51% |
+98,083
| New | +$6.86M |
|
69
BioMarin Pharmaceuticals
BMRN
$11.6B
| $6.61M | 0.5% |
87,472
-9,300
| -10% | -$760K |
|
|
CMPI
70
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $6.58M | 0.5% |
541,766
-7,036
| -1% | -$100K |
|
71
Cigna
CI
$73.7B
| $6.36M | 0.48% |
26,297
-1,444
| -5% | -$322K |
|
|
FNCH
72
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
| $6.3M | 0.48% |
+13,000
| New | +$6.62M |
|
73
Medtronic
MDT
$109B
| $6.2M | 0.47% |
52,501
+14,000
| +36% | +$1.64M |
|
|
VIRX
74
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $5.99M | 0.45% |
+647,556
| New | +$6.75M |
|
|
NCNA
75
NuCana
NCNA
$5.49M
| $5.56M | 0.42% |
223
+73
| +49% | +$2.03M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q1 2021 Portfolio in Review
As of Q1 2021, Sectoral Asset Management held 135 positions worth $1.32B, down 7% from $1.42B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Sectoral Asset Management withdrew a net $118M in Q1 2021, closing 22 positions and reducing 44 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $35M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Industrials.
Against the trend, Sectoral Asset Management opened a new position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares worth $33.4M.
- Sectoral Asset Management's largest Q1 2021 buy was Ortho Clinical Diagnostics Holdings plc Ordinary Shares: 1,730,500 shares worth $33.4M.
- Sectoral Asset Management added most to TG Therapeutics in Q1 2021, an estimated $14.8M increase.
- Sectoral Asset Management's biggest Q1 2021 reduction was Tandem Diabetes Care, cutting an estimated $40.6M.
- Sectoral Asset Management fully exited Acadia Pharmaceuticals in Q1 2021, selling an estimated $35M.
- Sectoral Asset Management's ten largest holdings make up 28% of its $1.32B portfolio in Q1 2021.
- Sectoral Asset Management opened 38 new positions and closed 22 in Q1 2021.
- Sectoral Asset Management's portfolio value fell 7% quarter-over-quarter to $1.32B.
Based on Sectoral Asset Management's 13F filing for Q1 2021, filed 14 May 2021.